Indications for: LUMIGAN
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
In a 12-month clinical study of patients with open angle glaucoma or ocular hypertension with an average baseline IOP of 23.5 mmHg, the IOP-lowering effect of Lumigan 0.01% once daily (in the evening) was up to 7.5 mmHg.
≥16yrs: 1 drop in affected eye once daily in the PM.
<16yrs: not recommended.
Do not exceed recommended dose. Intraocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Allow at least 5mins between application of other topical ophthalmic agents.
Conjunctival hyperemia, ocular effects (eg, edema, hemorrhage, irritation, pain, pruritus), hypertrichosis, eyelash growth, visual disturbances, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, keratitis, infection, abnormal liver function tests.
Renal (67%), fecal (25%). Half-life: ~45 minutes.
Generic Drug Availability:
Soln—2.5mL, 5mL, 7.5mL